Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

Gastroenterology

Volumn 146, Issue 2, 2014, Pages

  Panaccione, Remo ^a   Ghosh, Subrata ^a   Middleton, Stephen ^b   Márquez, Juan R ^c   Scott, Boyd B ^d   Flint, Laurence ^d   Van Hoogstraten, Hubert J F ^d   Chen, Annie C ^d   Zheng, Hanzhe ^d   Danese, Silvio ^e   Rutgeerts, Paul ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Clinica Las Americas   (Colombia)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biologic Treatment; Purine Antimetabolites; Tumor Necrosis Factor Inhibitors

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFUSION RELATED REACTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892737455     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.10.052     Document Type: Article

References (18)

1. S. Danese, and C. Fiocchi Ulcerative colitis N Engl J Med 365 2011 1713 1725
2. S.B. Hanauer Medical therapy for ulcerative colitis 2004 Gastroenterology 126 2004 1582 1592
3. W.A. Faubion Jr., E.V. Loftus Jr., and W.S. Harmsen et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
4. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
5. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 105 2010 501 523
6. E.F. Stange, S.P. Travis, and S. Vermeire et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis J Crohns Colitis 2 2008 1 23
7. S.P. Travis, E.F. Stange, and M. Lemann et al. European evidence-based consensus on the management of ulcerative colitis: current management J Crohns Colitis 2 2008 24 62
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline E6: Guideline for good clinical practice - E6 (R1). 1996. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf. Updated June 10, 1996. Accessed: August 5, 2013.
9. K. Reich, G. Wozel, and H. Zheng et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2) Br J Dermatol 168 2013 1325 1334
10. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
11. E.J. Irvine, B. Feagan, J. Rochon Canadian Crohn's Relapse Prevention Trial Study Group Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease Gastroenterology 106 1994 287 296
12. R.D. Hays, C.D. Sherbourne, and R.M. Mazel The RAND 36-Item Health Survey 1.0 Health Econ 2 1993 217 227
13. S. Ardizzone, G. Maconi, and A. Russo et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47 53
14. A.B. Hawthorne, R.F. Logan, and C.J. Hawkey et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20 22
15. D.P. Jewell, and S.C. Truelove Azathioprine in ulcerative colitis: final report on controlled therapeutic trial Br Med J 4 1974 627 630
16. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, D. Rachmilewitz, S. Lichtiger, G. D'Haens, R.H. Diamond, D.L. Broussard, K.L. Tang, C.J. van der Woude, and P. Rutgeerts Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
17. J.F. Colombel, P. Rutgeerts, and W. Reinisch et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
18. C.A. Siegel, S.R. Finlayson, and B.E. Sands et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model Clin Gastroenterol Hepatol 10 2012 46 51